Webinars.
Educational insights about GARD®
When you watch our webinars, you will learn in what ways GARD can support your testing needs. We cover essential topics that range from genomics and machine learning and why GARD has such robust prediction for in vitro sensitization testing, to difficult-to-test samples and quantitative potency assessment.
© SenzaGen
Interested in more information?
Contact us to discuss how the GARD assays can support your testing needs.
Nov 20, 2024
In vitro skin sensitization testing: Ensuring conclusive results for challenging samples
This webinar is a special re-run of our popular GARD® webinar to explore the recent advancement in Skin Sensitization testing, focusing on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines.
Key topics:
- NAMs and test strategies for skin sensitization testing of challenging samples.
- The applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.
- Case studies on Agrochemical Formulations, Formulated Lubricant Products, Indirectly Acting Haptens, Metals, Natural Extracts, Polymers, and UVCBs.
Oct 9, 2024
Advancing NAMs for Skin Sensitization Testing: Spotlight on Point-of-Departure, Challenging Substances, and Active Ingredients 
In this webinar, industry leaders from Lundbeck, Unilever, and Cargill, along with experts from SenzaGen explain the latest advancements in skin sensitization testing.
We explore the latest data from our GARD® platform on skin sensitization and highlight case studies from collaborative projects, including those with L’Oréal and ExxonMobil Biomedical Sciences.
If you missed SenzaGen’s scientific presentations at Eurotox this year, this webinar is your chance to catch up on the most recent developments.
June 27, 2024
Meta-analysis of GARD®data: Spotlight on in vitro quantitative assessment of skin sensitizing potency 
In this webinar, our expert presents a meta-analysis of GARD® data covering over 200 chemicals, including three blinded datasets generated in collaboration with industry partners: | L’Oréal | IFF | RIFM |
These data demonstrate how GARD® can estimate a Point of Departure (PoD) and be incorporated into downstream strategies for Quantitative Risk Assessment (QRA), contributing to the assessment of safe use levels of chemicals.
You will learn how the assay can be used to predict LLNA EC3 values, Human NOELs, and GHS/CLP classifications (1A or 1B).
April 23, 2024
2024 SOT recap: Advancing NAMs for Skin Sensitization Testing 
In case you missed SenzaGen’s poster presentations and scientific session at this year’s SOT, we are pleased to offer you a new opportunity to participate in this webinar! You will learn the latest GARD data from industry collaborations:
Corteva Agriscience | ExxonMobil Biomedical Sciences | L’Oréal | IFF | RIFM | Inotiv | Johnson Matthey | Sonova | Duearity
Mar 21, 2024
Introduction to GARD in Chinese
In this webinar you will get an introduction to the GARD technology in Chinese. Presented at PCHi 2024 in Shanghai, China.
Feb 07, 2024
Spotlight on Difficult-to-Test samples: Ensuring conclusive results for in vitro Skin Sensitization assessment
In this webinar, you’ll learn about the recent advancement in GARD® for Skin Sensitization assessment, with a specific focus on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines:
Agrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs
Dec 14, 2023
Safety of acrylate monomers, metals and other materials used in medical device development
In this webinar, you’ll explore the effective utilization of in vitro methods for safety assessment of materials during product development of Medical Devices. Discover how this approach can aid in:
Selecting the right material | Developing new materials | Optimizing production | Choosing the appropriate sterilization method
Oct 18, 2023
Latest GARD® innovation and research in in vitro skin and respiratory sensitization
In this webinar, you’ll explore the latest GARD® data on skin and respiratory sensitization. Emily Reinke from Inotiv-RTP will present a project in collaboration with NIH and Burleson Research Technologies. We’ll also showcase recent projects with industry partners: Merck | Johnson Matthey | ExxonMobil Biomedical Sciences | International Flavors & Fragrances (IFF) | Duearity | Inotiv-RTP
June 12, 2023
Time for a Change: Evidence-Based Approaches for the Biological Safety Assessment of Medical Devices
In this webinar Ron Brown, toxicologist and former FDA risk assessor, will outline the need for a new and more agile approach for the biological safety assessment of medical devices. *
May 24, 2023
Using in vitro data in your CE marking submission of Medical Devices
In this webinar you will learn how you can avoid animal testing and accelerate time to market by using results from in vitro testing for the endpoints of cytotoxicity, skin irritation and skin sensitization in your biological evaluation for CE-marking of your medical device in line with the EU Medical Device Regulation 2017/745, the MDR. *
Apr 26, 2023
Recap Webinar on SenzaGen’s 2023 SOT Exhibitor Hosted Session
Together with guest speakers Allison Greminger, PhD, DABT, of Exxon Mobil Biomedical Sciences, Inc. and Gretchen Ritacco of Research Institute for Fragrance Materials, Inc. (RIFM), SenzaGen’s Andy Forreryd, PhD. will present new GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers, and the potential to further broaden the GARD® applicability.
Feb 22, 2023
Overcoming challenges in skin sensitization testing with GARDskin OECD TG 442E
Together with guest speakers Dr Marco Corvaro, Technical Team Leader, Regulatory Toxicology at Corteva Agriscience and Gretchen Ritacco, Principal Scientist at the Research Institute for Fragrance Materials (RIFM), we discuss the challenges in skin sensitization testing and present new scientific data on agrochemical formulations, “difficult-to-test” substances, potency assessment and the potential to further broaden the applicability of the GARD assay to assess the endpoint of photosensitization.
Jan 30, 2023
Chinese Introduction to GARD
In this webinar you will get an introduction to GARD in chinese. Presented at PCHi 2023, Expo & SHSOT Forum, Guangzhou, China.
Jan 24, 2023
Safety and Efficacy Evaluation of Cosmetic Products and Ingredients
Together with experts from CEHTRA, GenEvolutioN®, Laboratoire WatchFrog and PKDERM, we presented an overview of innovative in vitro methods and how to integrate them into the evaluation of safety and efficacy of cosmetic products and ingredients.
Oct 26, 2022
How to use in vitro assays in your biological evaluation
Our Medical Device and ISO expert Rose-Marie Jenvert, PhD will tell you more about how you can use in vitro methods for the biological evaluation of medical devices, now offered at our GLP-certified laboratories. She will also introduce our expanded medical device offering that provides guidance through the comprehensive process of biological evaluation to comply with MDR requirements.
Oct 12, 2022
Recap on SenzaGen’s 2022 ICT Scientific Session
Our skin sensitization expert Dr Andy Forreryd will present new scientific data on agrochemical formulations generated in collaboration with Corteva Agriscience, “difficult-to-test” substances and potency assessment.
July 13, 2022
OECD update
Join this webinar led by our skin sensitization specialist Dr Andy Forreryd to learn the features and benefits of GARDskin and how the method can be used to fill data gaps during regulatory testing and product development.
May 25, 2022
Medical Devices’ principal mode of action by physical means: case studies on 3D reconstructed human tissues
By Dr Laura Ceriotti@VitroScreen, Dr Paolo Buratti@VitroScreen
This webinar showcase the opportunities offered by 3D reconstructed human tissues to demonstrate the physical mode of action of medical devices in line with the requirements and ethical criteria of the EU Medical Devices Regulation (MDR) 2017/745.
Key takeaways
How the principles of the 3Rs are applied in the MDR’s requirements.
How 3D reconstructed human tissues become a robust tool to define and demonstrate the principal mode of action of medical devices.
How to assess on a case by case approach the physical mode of action of medical devices according to their different therapeutic areas.
April 28, 2022
SenzaGen’s 2022 SOT Scientific Session: New GARD® data on agrochemical formulations, fragrance materials, medical devices and metals
By Dr Andy Forreryd@SenzaGen, Dr Christopher Choi@Takasago, Dr Karla Lienau@Sonova
Together with guest speakers from Takasago and Sonova, we will present the latest user cases where the in vitro GARD assays have been used for skin sensitization testing with a focus on the quantitative potency assessment. New GARD data on agrochemical formulations, fragrance materials, medical devices and metals will be presented.
Feb 17, 2022
Safer Medical Devices: In vitro assays as part of your biological evaluation
By Dr Rose-Marie Jenvert
In this webinar, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices, now offered at our GLP certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR.
Jan 20, 2022
Why choose GARD for skin sensitization testing?
By Dr Andy Forreryd
In this webinar you will get:
An introduction to GARD: How the genomic and machine learning-based technology works and its applications
Case studies: “Difficult-to-test” samples such as complex mixtures, pre/pro- haptens and substances with low water solubility
Case studies: In vitro skin sensitization assessment of medical devices using both saline and oil as extraction vehicles
Case studies: In vitro quantitative potency assessment as an alternative to LLNA
Nov 18, 2021
Safety Testing of Cosmetic Products
Joint webinar
Nov 11, 2021
Recap on SenzaGen’s Eurotox Industry Symposium: Filling data gaps in skin sensitization testing
By Dr Andy Forreryd, Dr Marco Corvaro, Dr Peter Mohlin
Sep 16, 2021
New opportunity: How is GARD used for skin sensitization testing?
By Dr Rose-Marie Jenvert
May 27, 2021
Skin Sensitizing Potency Assessment: Filling in data gaps
By Dr Andy Forreryd and Dr Tim Lindberg
April 28, 2021
In vitro technology replacing animal models for skin sensitization testing
By Anna Chérouvrier Hansson and Ulrika T Mattson
April 14, 2021
SenzaGen’s 2021 SOT poster presentations
By Dr Henrik Johansson and Dr Ron Brown
- Poster #1. Quantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response | Download a copy
- Poster #2. Applicability Domain of the GARD™skin Medical Device Test for In Vitro Skin Sensitization Testing of Medical Devices (MDCPSS Best Overall Abstract) | Download a copy
March 11, 2021
Joint webinar in French: Cosmetic Safety 3.0 – Webinaire France (new session)
By PKDerm, GenEvolutioN, CEHTRA and SenzaGen
February 25, 2021
How is GARD™ used for sensitization testing?
By Rose-Marie Jenvert, PhD, SenzaGen
January 27, 2021
Why choose GARD™ for sensitization testing?
By Andy Forreryd, PhD, SenzaGen
October 21, 2020
Safer Medical Devices – in vitro skin sensitization testing with human relevance and high accuracy
By Rose-Marie Jenvert, PhD, and Joshua Schmidt, PhD, SenzaGen
October 6, 2020
Joint webinar in French: Cosmetic Safety 3.0 – Webinaire France
By PKDerm, GenEvolutioN, SenzaGen
September 15, 2020
Joint webinar: Your Guide to GARD®
– New generation skin sensitisation testing technologies explained
By Carol Treasure, PhD, XCellR8 and Andy Forreryd, PhD, SenzaGen AB
June 17, 2020
Web-based launch: The NEW GARDskin Dose-Response
By Andy Forreryd, PhD, SenzaGen AB
May 26, 2020
Genomics and Machine Learning for In Vitro Sensitization Testing of Challenging Chemicals
By Henrik Johansson, PhD, and Andy Forreryd, PhD, SenzaGen AB
March 26, 2020
Web-based conference on “Difficult-to-test” substances and regulatory testing
By Andy Forreryd, SenzaGen AB and guest speakers from Eurofins, Lubrizol and MB Research Labs
Session recordings
Dr Andy Forreryd, SenzaGen
Helge Gehrke, Eurofins BioPharma Product Testing
Dr. George DeGeorge, MB Research Labs
February, 2020
In vitro sensitization testing based on genomics and machine learning
By Angelica Johansson, SenzaGen AB
October, 2019
In vitro sensitization testing of Medical Devices – GARDskin Medical Device
By Rose-Marie Jenvert, PhD, SenzaGen
September 2019
How are the in vitro GARD™ assays used in real life? – Cases and applications for testing of skin and respiratory sensitizers
By Andy Forreryd, PhD, SenzaGen
